Information  X 
Enter a valid email address

Oxford Biomedica PLC (OXB)

  Print   

Tuesday 23 June, 2020

Oxford Biomedica PLC

Result of Annual General Meeting

RNS Number : 8437Q
Oxford Biomedica PLC
23 June 2020
 

 

 

 

Oxford Biomedica

Result of Annual General Meeting

 

Oxford, UK - 23 June 2020: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in Oxford. 

 

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

 

· Resolution 13: to authorise the Directors, pursuant to section 551 of the Companies Act 2006, to allot shares (or grant rights to subscribe for, or convert securities into, shares), up to an aggregate nominal amount of two-thirds of the presently issued shares, one-third of which may only be used in connection with a rights issue in favour of shareholders;

· Resolution 14: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares;

· Resolution 15: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment;

· Resolution 16: to adopt new articles of association in order to update the Company's current articles of association, which were adopted in 2010; and

· Resolution 17: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxb.com

 

Copies of the document setting out the above resolutions passed at the 2020 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

The results of the proxy voting in advance of the meeting are shown below. On the Record Date (19 June 2020) there were 77,002,369 ordinary shares of 50 pence each in issue, each carrying one vote per share.

 

 

 

Resolution

 

Votes

For

Votes at

Chairman's

Discretion

Votes at

other proxy

Discretion

 

Votes

Against

 

Votes

Withheld*

 

Total

votes cast

Result









Ordinary resolutions














1

49,841,735

917

0

0

113,171

49,842,652

Passed









2

48,970,356

917

0

909,694

74,856

49,880,967

Passed









3

47,679,014

917

0

2,202,867

73,024

49,882,798

Passed

4

 

 






 

WITHDRAWN









5

49,752,318

917

0

131,635

70,953

49,884,870

Passed









6

49,751,723

917

0

132,230

70,953

49,884,870

Passed









7

46,661,012

917

0

3,222,941

70,953

49,884,870

Passed









8

47,680,935

917

0

2,203,017

70,953

49,884,869

Passed









9

48,322,433

917

0

1,561,520

70,953

49,884,870

Passed









10

48,322,702

917

0

1,561,277

70,927

49,884,896

Passed









11

48,872,224

917

0

7,169

75,513

49,880,310

Passed









12

49,871,544

917

0

9,284

74,078

49,881,745

Passed









13

47,858,386

917

0

592,553

1,503,967

48,451,856

Passed

 

Special resolutions














14

48,112,773

917

0

336,725

1,505,408

48,450,415

Passed









15

48,111,711

917

0

337,790

1,505,405

48,450,418

Passed









16

49,878,294

917

0

1,370

75,242

49,880,581

Passed









17

49,177,732

917

0

705,017

72,157

49,883,666

Passed









 

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

 

 

-Ends-

 

 

Enquiries:

 

 

Oxford Biomedica plc

 

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Catherine Isted, Head of Corporate Development & IR

 

 

 

 

T: +44 (0)1865 783 000

T: +44 (0)1865 783 000

T: +44 (0)1865 954 161 / E: [email protected]

 

Consilium Strategic Communications

 

Mary-Jane Elliott/Matthew Neal

 

 

T: +44 (0)20 3709 5700

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at  www.oxb.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGKKNBQPBKDBAB

a d v e r t i s e m e n t